References
- Faunce, T. A. 2007a. “Global Intellectual Property Protection for “Innovative” Pharmaceuticals: Challenges for Bioethics and Health Law.” In Globalization and Health: Challenges for Health Law and Bioethics, edited by B. Bennett and G. F. Tomossy, 87–108. Dordrecht: Springer.
- Faunce, T. A. 2007b. “Reference Pricing for Pharmaceuticals: Is the Australia–United States Free Trade Agreement Affecting Australia's Pharmaceutical Benefits Scheme?” Medical Journal of Australia 187: 240–242.
- Faunce, T., J. Bai, and D. Nguyen. 2010. “Impact of the Australia–US Free Trade Agreement on Australian Medicines Regulation and Prices.” Journal of Generic Medicines 7 (1): 18–29. doi:10.1057/jgm.2009.40.
- US Department of Commerce, International Trade Administration. 2004. Pharmaceutical price controls in OECD countries. Implications for US consumers, pricing, research and development and innovation. Washington: US Department of Commerce.